Company
Biotech developing Syk inhibitors to treat autoimmune, neuroinflammatory and hematologic conditions
Brisbane, QLD
Every investor coverage indicates participated in a round Lucia Bio raised.
Companies Lucia Bio acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
Stories naming Lucia Bio. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Queensland drug developer Lucia Bio added $2 million to its seed round from UniQuest Extension Fund and Uniseed-managed funds, bringing its overall raise to $3 million ahead of a planned Series A.
Molecule to Medicine announces Curlew Bio as the second venture in its Brisbane Pod, with Uniquest Expansion Fund backing, to develop immunological therapies for inflammatory disease.
UniQuest and Molecule to Medicine have formed Curlew Bio to develop anti-inflammatory drugs, backed by $1 million from UniQuest's Extension Fund; the article also recalls Novartis's 2015 purchase of Spinifex Pharmaceuticals.